Meeting Report: Risk Assessment of Tamiflu Use Under Pandemic Conditions

On 3 October 2007, 40 participants with diverse expertise attended the workshop Tamiflu and the Environment: Implications of Use under Pandemic Conditions to assess the potential human health impact and environmental hazards associated with use of Tamiflu during an influenza pandemic. Based on the identification and risk-ranking of knowledge gaps, the consensus was that oseltamivir ethylester-phosphate (OE-P) and oseltamivir carboxylate (OC) were unlikely to pose an ecotoxicologic hazard to freshwater organisms. OC in river water might hasten the generation of OC-resistance in wildfowl, but this possibility seems less likely than the potential disruption that could be posed by OC and other pharmaceuticals to the operation of sewage treatment plants. The work-group members agreed on the following research priorities: a) available data on the ecotoxicology of OE-P and OC should be published; b) risk should be assessed for OC-contaminated river water generating OC-resistant viruses in wildfowl; c) sewage treatment plant functioning due to microbial inhibition by neuraminidase inhibitors and other antimicrobials used during a pandemic should be investigated; and d) realistic worst-case exposure scenarios should be developed. Additional modeling would be useful to identify localized areas within river catchments that might be prone to high pharmaceutical concentrations in sewage treatment plant effluent. Ongoing seasonal use of Tamiflu in Japan offers opportunities for researchers to assess how much OC enters and persists in the aquatic environment.

[1]  D. Smee,et al.  Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza , 2002, Expert opinion on investigational drugs.

[2]  R. Webster,et al.  Neuraminidase Inhibitor-Resistant Influenza Viruses May Differ Substantially in Fitness and Transmissibility , 2005, Antimicrobial Agents and Chemotherapy.

[3]  B. Levin,et al.  Antiviral Resistance and the Control of Pandemic Influenza , 2007, PLoS medicine.

[4]  Mitchell S. Wilbanks,et al.  EUROPEAN CENTRE FOR ECOTOXICOLOGY AND TOXICOLOGY OF CHEMICALS , 2005 .

[5]  F. Aoki,et al.  Influenza Virus Susceptibility and Resistance to Oseltamivir , 2005, Antiviral therapy.

[6]  D. Cummings,et al.  Strategies for mitigating an influenza pandemic , 2006, Nature.

[7]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[8]  John J. Treanor,et al.  Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza , 2000 .

[9]  B. Lina,et al.  Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. , 2005, Antiviral research.

[10]  A. Amonsin,et al.  H5N1 Oseltamivir-resistance detection by real-time PCR using two high sensitivity labeled TaqMan probes , 2006, Journal of Virological Methods.

[11]  P. Ward,et al.  Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. , 2005, The Journal of antimicrobial chemotherapy.

[12]  J. McKimm-Breschkin,et al.  News about influenza B drug resistance that cannot be ignored. , 2007, JAMA.

[13]  P. Ward,et al.  Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. , 2003, Archives of internal medicine.

[14]  Liang Tong,et al.  Bacterial neuraminidase facilitates mucosal infection by participating in biofilm production. , 2006, The Journal of clinical investigation.

[15]  F. Hayden,et al.  Antivirals for influenza: historical perspectives and lessons learned. , 2006, Antiviral research.

[16]  N. Roberts,et al.  Treatment of influenza with neuraminidase inhibitors: virological implications. , 2001, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[17]  I. Barr,et al.  Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. , 2007, Antiviral research.

[18]  P. Ward,et al.  Oral oseltamivir treatment of influenza in children , 2001, The Pediatric infectious disease journal.

[19]  P. Grenni,et al.  Degradation of the antiviral drug oseltamivir carboxylate in surface water samples , 2007 .

[20]  Andrew C. Singer,et al.  Potential Risks Associated with the Proposed Widespread Use of Tamiflu , 2006, Environmental health perspectives.

[21]  S. Trottier,et al.  Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial , 2000, The Lancet.

[22]  Akio Yamada,et al.  OECD Guidelines for Testing of Chemicals , 1982 .

[23]  A global assessment of chemical effluent dilution capacities from a macro-scale hydrological model , 2006 .

[24]  Mats Tysklind,et al.  Antiviral Oseltamivir Is not Removed or Degraded in Normal Sewage Water Treatment: Implications for Development of Resistance by Influenza A Virus , 2007, PloS one.

[25]  Sandra Mounier-Jack,et al.  Progress and shortcomings in European national strategic plans for pandemic influenza. , 2007, Bulletin of the World Health Organization.